LENZ Therapeutics, Inc.
LENZNASDAQHealthcare● Active
$6.72
$-0.29(-4.14%)
Market Cap$210701528
P/E Ratio—
52W High$50.4
52W Low$6.61
LENZ Therapeutics, Inc. (LENZ) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LENZ · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $19.09M | $0.00M | $0.00M | $15.00M | $0.00M |
| Cost of Revenue | $0.70M | $0.06M | $0.00M | $0.00M | $0.73M |
| Gross Profit | $18.38M | ($0.06M) | $0.00M | $15.00M | ($0.73M) |
| Gross Margin %(computed) | 96.31% | — | — | 100.00% | — |
| Operating Expenses | |||||
| R&D Expenses | $18.67M | $29.80M | $59.50M | $21.13M | $37.93M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $109.52M | $58.55M | $72.43M | $25.48M | $59.71M |
| Operating Income | ($91.14M) | ($58.61M) | ($72.43M) | ($10.48M) | ($60.44M) |
| Operating Margin %(computed) | -477.46% | — | — | -69.89% | — |
| Interest Income | $9.76M | $8.55M | $2.19M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($81.63M) | ($49.77M) | ($70.15M) | ($10.46M) | ($70.76M) |
| Income Tax Expense | $0.50M | $0.00M | ($0.18M) | $0.35M | $0.00M |
| Net Income | ($82.13M) | ($49.77M) | ($69.97M) | ($10.81M) | ($70.76M) |
| Net Margin %(computed) | -430.25% | — | — | -72.07% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.85 | $-2.34 | $-15.30 | $-12.89 | $-8.54 |
| Wtd Avg Shares | 28.81M | 21.28M | 8.15M | 7.84M | 8.29M |
| EBITDA | ($90.85M) | ($49.71M) | ($72.41M) | ($10.47M) | ($70.03M) |
| EBITDA Margin %(computed) | -475.96% | — | — | -69.83% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more LENZ Therapeutics, Inc. data
About LENZ Therapeutics, Inc. (LENZ) Income Statement
LENZ Therapeutics, Inc. (LENZ) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, LENZ reported revenue of $0.02B, gross profit of $0.02B (gross margin 96.31%), and net income of ($0.08B) — a net profit margin of -430.25%.
Frequently asked questions
LENZ · 4 questionsLENZ Therapeutics, Inc. (LENZ) reported revenue of $0.02B for 2025, up —% year-over-year.
LENZ revenueLENZ salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08